Erratum: Randomized, Open-Label, Phase III Study of Tilsotolimod in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced Refractory Melanoma (ILLUMINATE-301)

J Clin Oncol. 2025 Aug 10;43(23):2658. doi: 10.1200/JCO-25-01412. Epub 2025 Jun 25.
No abstract available

Publication types

  • Published Erratum